米托坦(Lysodren)说明书 

通用名称：Mitotane 

品牌名称：Lysodren 

其他名称：米托坦，密妥坦，曼托坦，氯苯二氯乙烷，解腺瘤片,解腺瘤，Mitotane，Lysodren，Chloditan，Chlonlithane 

适应症： 

本品适用于以下患者治疗： 

无法手术的、功能性和非功能性肾上腺皮质癌、肾上腺皮质增生以及肿瘤所致的皮质醇增多症。 

用法用量： 

对于18岁以下的儿童，此药的疗效及安全性尚未完全确定，医生会根据患者的体重或身体表面面积来决定每日服用的剂量。 

成人每日剂量为1至6克(可分3至4次服)，及后可逐步递增至每日8至10克。一般建议每日最高剂量为18克。 

用药禁忌： 

对此药有过敏反应者不宜服用。 

用药注意: 

对于轻微至中等程度的肝脏或肾脏受损的患者，剂量可能需要根据药物的血液浓度相应下调。 

对于严重程度的肝脏或肾脏受损的患者则不建议服用此药。 

副作用及不良反应: 

密妥坦 (米托坦)最常见的副作用包括：抑制中枢神经系统、眩晕、嗜睡、皮肤出疹、食欲不振、恶心、呕吐、腹泻等。 

其他副作用:头痛、高血压、体位性低血压、抑郁、神志不清、肌肉震颤、出血性膀胱炎等。 

药物相互作用: 

1. Spironolactone (螺内酯)可降低此药的疗效，故不建议同时使用。 

2. 酒精、第一代抗组织胺药物(sedative antihistamine)、镇静安眠药、吗啡类止痛药、抗癫痫症药等具中枢神经系统抑制的作用，合并使用可增加相关的副作用如嗜睡、眩晕等。 

3. 此药可增加肝脏对某些药物(如部份抗癫痫症药物、巴比妥类药物、Warfarin华法林等)的代谢，合并使用可使后者的药效下降，故需特别监察。 

4. 服药者在使用其他药物前请先咨询主治医生意见。 

注意事项： 

1. 此药乃化疗药物，在处理及弃置药物时须小心谨慎。 

2. 饱肚服用此药可增加吸收。 

3. 此药可抑制中枢神经系统，引致嗜睡、眩晕等，故在服药期间尽量避免驾驶或操作机械等需要高度精神集中力的活动。 

4. 服药者如出现感染、创伤或其他疾病，应立即找医生诊治，以避免出现急性肾上腺皮质功能不全。 

保存： 

密闭、干燥，于阴凉处保存。 

Generic Name: mitotane
Dosage Form: tablet

. Last updated on Jan 1, 2020.

WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

In patients taking Lysodren, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue Lysodren until recovery [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)].

Lysodren is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

The recommended initial dose of Lysodren is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated.

Lysodren is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Adrenal Crisis in the Setting of Shock or Severe Trauma

Discontinue Lysodren until recovery [see Warnings and Precautions (5.1)].

Central Nervous System (CNS) Toxicity

Discontinue Lysodren until symptoms resolve. Seven to 10 days after symptoms resolve, restart at a lower dose (for example, decrease by 500-1000 mg) [see Warnings and Precautions (5.2)].

500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with "BL" over "L1" on the other side.

None.

In patients taking Lysodren, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock, and discontinue Lysodren until recovery [see Dosage and Administration (2.2)].

CNS toxicity, including sedation, lethargy, and vertigo, occurs with Lysodren treatment. Mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity.

Treatment with Lysodren can cause adrenal insufficiency. Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement.

Lysodren can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes, such as preterm births and early pregnancy loss, can occur in patients exposed to mitotane during pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Lysodren and after discontinuation of treatment for as long as mitotane plasma levels are detectable [see Use in Specific Populations (8.1, 8.3)].

Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving Lysodren. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described. Advise female patients to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [seeAdverse Reactions (6)].

The following adverse reactions are discussed in greater detail in other sections of the label:

•  Adrenal Crisis in the Setting of Shock or Severe Trauma [see Warnings and Precautions (5.1)]

•   CNS Toxicity [seeWarnings and Precautions (5.2)]

•   Adrenal Insufficiency [seeWarnings and Precautions (5.3)]
•   Ovarian macrocysts [seeWarnings and Precautions (5.5)]

The following adverse reactions associated with the use of Lysodren were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

Common adverse reactions occurring with Lysodren treatment include:

•Anorexia, nausea, vomiting, and diarrhea (80%)

•Depression, dizziness, or vertigo (15%-40%)

•Rash (15%)•Neutropenia•Growth retardation, hypothyroidism

•Confusion, headache, ataxia, mental impairment, weakness, dysarthria

•Maculopathy•Hepatitis, elevation of liver enzymes•Gynecomastia

•   Hypercholesterolemia, hypertriglyceridemia

• Decreased blood androstenedione and decreased blood testosterone in females, increased sex hormone binding globulin in females      and males, decreased blood free testosterone in males.

Less common adverse reactions include: visual blurring, diplopia, lens opacity, retinopathy, prolonged bleeding time, hematuria, hemorrhagic cystitis, albuminuria, hypertension, orthostatic hypotension, flushing, generalized aching, and fever.

Mitotane is a strong inducer of cytochrome P450 3A4 (CYP3A4). Monitor patients for a change in dosage requirements for the concomitant drug when administering Lysodren to patients receiving drugs that are substrates of CYP3A4.

When administering coumarin-type anticoagulants to patients receiving Lysodren, monitor coagulation tests and adjust the anticoagulant dose as needed.

Risk Summary

Lysodren can cause fetal harm. Limited postmarketing cases report preterm births and early pregnancy loss in women treated with Lysodren during pregnancy. Animal reproduction studies have not been conducted with mitotane. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Risk Summary

Mitotane is excreted in human milk; however, the effect of Lysodren on the breastfed infant, or effect on milk production is unknown. Because of the potential for serious adverse reactions in the breastfed infant, advise nursing women that breastfeeding is not recommended during treatment with Lysodren and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

Contraception

Lysodren can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise female patients of reproductive potential to use effective contraception during treatment with Lysodren and after discontinuation of therapy for as long as mitotane plasma levels are detectable [see Clinical Pharmacology (12.3)].

Safety and effectiveness in pediatric patients have not been established.

Clinical studies of Lysodren did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Hepatic impairment may interfere with the metabolism of mitotane and the drug may accumulate. Administer Lysodren with caution to patients with hepatic impairment.

Lysodren (mitotane) is an oral adrenal cytotoxic agent. The chemical name is (±)-1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (also known as o,p′-DDD). The chemical structure is:

Mitotane is a white granular solid composed of clear colorless crystals. It is tasteless and has a slight pleasant aromatic odor. It is soluble in ethanol and has a molecular weight of 320.05.

Inactive ingredients in Lysodren are: microcrystalline cellulose, polyethylene glycol 3350, silicon dioxide, and starch.

Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid concentrations and increased formation of 6-β-hydroxycortisol have been reported.

The pharmacodynamics of mitotane are unknown.

Absorption

Following oral administration of Lysodren, 40% of the dose is absorbed.

Distribution

Mitotane is found in most tissues of the body; however, fat is the primary site of distribution.

Elimination

Following discontinuation of mitotane, the plasma terminal half-life ranges from 18 to 159 days (median 53 days).

Metabolism

Mitotane is converted to a water-soluble metabolite.

Excretion

No unchanged mitotane is found in urine or bile. Approximately 10% of the administered dose is recovered in the urine as a water-soluble metabolite. A variable amount of metabolite (1%-17%) is excreted in the bile.

The carcinogenicity and mutagenicity of mitotane are unknown.

15 REFERENCES

1.OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

Lysodren tablets are supplied as 500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with "BL" over "L1" on the other side.

100 tablets per bottle: NDC 76336-080-60

Store bottles at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F-86°F).

Mitotane is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

Adrenal Crisis

•

Advise patients to discontinue Lysodren in the case of shock or severe trauma and contact their healthcare provider immediately.

•

Advise patients to tell their healthcare provider of any planned surgeries.

Ovarian Macrocysts

• Advise premenopausal women to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [see Warnings and Precautions(5.5)].

Embryo-Fetal Toxicity

•

Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)].

•

Advise females of reproductive potential to use effective contraception during treatment and after discontinuation of treatment for as long as instructed by their healthcare provider [see Use in Specific Populations (8.3)].

Lactation

•

Advise females who are nursing not to breastfeed during treatment with Lysodren [see Use in Specific Populations (8.2)].

Address medical inquiries to:
Direct Success Inc.
1710 Hwy 34
Farmingdale, NJ 07727
844-597-6373
844 Lysodren
Fax: (855) 674-6767

Manufactured by:
Corden Pharma Latina S.p.A.
Via del Murillo Km. 2.800
04013 Sermoneta (Latina)
Italy

For : HRA Pharma Rare Diseases, France

NDC 76336-080-60

Lysodren
(mitotane) tablets, for oral use

EACH TABLET CONTAINS
500 mg

100 Tablets
Rx only

HRA Pharma Rare Diseases

HRA Pharma Rare Diseases